Profluent Bio Valuation, Funding & Investors
Profluent Bio is valued at $30M as of August 2022.
Last Profluent Bio valuation
$30M
Seed · Aug 2022
Last Profluent Bio funding round
$106M
Undisclosed stage · Nov 2025
Cumulative funding Profluent Bio raised
$150M
across 3 funding rounds
Key investors in Profluent Bio
Insight Partners
Air Street Capital
Spark Capital
AIX Ventures
Altimeter Capital
Bezos Expeditions
About Profluent Bio
Profluent Bio is a South San Francisco-headquartered biotechnology company pioneering AI-driven protein design to create functional proteins for therapeutics and industrial applications. Founded in 2022, it leverages large language models adapted for biology to engineer proteins that outperform natural sequences in binding affinity and stability.
Founded
2022
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Licensing
Valuation
$30M (Aug 2022)
Profluent Bio Valuation
Profluent Bio is currently valued at $30M, based on its seed round in August 2022.
The $9M round was led by Insight Partners, with participation from AIX Ventures, Air Street Capital and Phoenix Venture Partners.
Profluent Bio valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Aug 2022 | Seed | $30M |
Profluent Bio Funding History
Profluent Bio has raised a total of $150M across 3 funding rounds.
Profluent Bio's first fundraising round was a $9M seed round in August 2022. The most recent completed round was a $106M undisclosed-stage round in November 2025.
Profluent Bio funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Nov 2025 | Undisclosed stage | Altimeter Capital (lead); Bezos Expeditions (lead); Air Street Capital; Spark Capital; Insight Partners | $106M | - | Profluent Bio is an AI-first company founded in 2022 and headquartered in Emeryville, California, specializing in de novo protein design to make biology programmable. It develops frontier AI models for designing genome editors, antibodies, enzymes, and other biologics, targeting applications in therapeutics, diagnostics, agriculture, and biomanufacturing. The company leverages massive datasets, including a protein catalog of 115 billion unique sequences equivalent to 20 trillion tokens, to train transformer-based models that generate novel proteins validated through wet-lab testing. On November 19, 2025, Profluent announced a $106 million financing round co-led by Altimeter Capital and Bezos Expeditions, with participation from existing investors Spark Capital, Insight Partners, and Air Street Capital. This Series B round brings the company's total funding to $150 million and will fund scaling of its AI foundation models, expansion of automated wet-lab capacity, and commercial growth across key verticals. The capital aims to accelerate progress toward dosing the first human patient with an AI-designed therapeutic. Profluent has demonstrated commercial traction through partnerships such as a multi-year collaboration with Corteva Agriscience for next-generation crops, a strategic alliance with Revvity for precise adenine deaminases, and work with Integrated DNA Technologies on research reagents. Its open-source OpenCRISPR-1 gene editor is adopted by thousands of commercial operations, academic researchers, and major pharma companies. Additional partners include The Rett Syndrome Research Trust, validating the platform's expansion beyond gene editing into antibodies, antigens, and enzymes. Investors highlight Profluent's combination of AI, biology, and therapeutic expertise amid scaling laws in AI, positioning it to transform multi-trillion-dollar markets by writing biology rather than just reading it. The round underscores confidence in Profluent's technical originality, scientific rigor, and execution speed as it defines the shift to programmable biology. |
| Mar 2024 | Undisclosed stage | Spark Capital (lead); AIX Ventures; Air Street Capital; Convergent Ventures; Insight Partners; Jeff Dean | $35M | - | Profluent Bio is a Berkeley, CA-based AI-first protein design company founded in 2022 by Ali Madani and Alexander Meeske. The company develops deep generative models, including large language models (LLMs), to design and validate novel, functional proteins, aiming to revolutionize biomedicine by making biology programmable. Its technology has been validated through a peer-reviewed paper in Nature Biotechnology demonstrating LLMs generating de novo proteins that function as well as naturally evolved ones. Profluent applies its platform initially to gene editing, enhancing CRISPR systems by tuning existing scaffolds or creating new ones from scratch for patient-specific therapeutics. On March 21, 2024, Profluent announced a $35 million funding round led by Spark Capital, with participation from existing investors Insight Partners and Air Street Capital, plus a syndicate of angel investors from OpenAI, Salesforce, Octant Bio, and Google, including Jeff Dean, Chief Scientist at Google DeepMind. This brought the company's total funding to $44 million, following a prior $9 million raise from Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. Spark Capital general partners Fraser Kelton and Nabeel Hyatt joined the board as part of the deal. The funding supports Profluent's next growth stage, focusing on advancing proprietary LLMs and datasets, enhancing wet lab capabilities, and developing CRISPR gene editing innovations. The company emphasizes partnerships as core to its business model, evaluating collaborations with leaders in therapeutic verticals. Leadership includes CEO Ali Madani, Chief Business Officer Hilary Eaton with gene editing experience from Tome, Vor, and Editas, and VP of Gene Editing Peter Cameron from Spotlight and Caribou. Profluent positions itself at the intersection of AI and CRISPR to enable custom-designed enzymes and new editing modalities, transforming natural enzymes like Cas9 into therapeutics. |
| Aug 2022 | Seed | Insight Partners (lead); AIX Ventures; Air Street Capital; Phoenix Venture Partners | $9M | $30M | Profluent Bio raised $9 million in a Series Seed round on August 20, 2022, from Air Street Capital, AIX Ventures, Convergent Ventures, and Insight Partners. The post-money valuation was $30 million, with a price per share of $3.13 and 2,880,000 shares outstanding. This was the company's first funding round, supporting its early-stage development in AI-driven protein design and gene editing for biomedicine and agriculture. |
Who has invested in Profluent Bio?
9 investors have backed Profluent Bio across its funding rounds, including Insight Partners, Air Street Capital, Spark Capital, AIX Ventures, Altimeter Capital and Bezos Expeditions.
Lead investors include Altimeter Capital, Bezos Expeditions, Spark Capital and Insight Partners.
Profluent Bio Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
 St. Peter Port | 3 | Participant | Aug 2022 | |
| New York City, NY | 3 | Lead | Aug 2022 | |
| San Francisco, CA | 2 | Participant | Aug 2022 | |
| San Francisco, CA | 2 | Lead | Mar 2024 | |
| San Francisco, CA | 1 | Participant | Aug 2022 | |
| San Francisco, CA | 1 | Lead | Nov 2025 | |
| San Francisco, CA | 1 | Participant | Mar 2024 | |
This data is available for Pro users. Sign up to see all 9 Profluent Bio investors. Start Free Trial | ||||
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small}
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialProfluent Bio Competitors
Profluent Bio competitors include listed companies like Gensight Biologics and BeyondSpring, and private ones like Aecor Bio, Talus Bio, Salt AI and AirezIQ.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| San Francisco, CA | Private | - | - | $30M | - | |
| Seattle, WA | Private | - | - | $31M | - | |
| Los Angeles, CA | Private | - | - | $29M | - | |
| Colorado Springs, CO | Private | - | - | $30M | - | |
 France | Publicly listed | $1K | ($10M) | $30M | 4.5x | |
| United States | Publicly listed | - | ($9M) | $30M | - |
Profluent Bio Public Comps
Profluent Bio is still privately-owned, but its public comps include Gensight Biologics, BeyondSpring, Barinthus Biotherapeutics, Oncocross, TAO Synergies, Evaxion, Spirit Scientific Co, Maat Pharma, Sprint Bioscience and Kyntra Bio.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1K | ($10M) | 36474.6x | 4.5x | (4.2x) | - | |||
| - | ($9M) | - | - | (2.7x) | - | |||
| - | ($63M) | - | - | - | - | |||
| $270K | ($6M) | 65.3x | - | (3.0x) | - | |||
| $299K | ($29M) | 109.6x | - | (1.1x) | - | |||
| $8M | ($7M) | 2.9x | 10.3x | (3.0x) | - | |||
| $9M | $2M | 2.9x | - | 14.6x | - | |||
| $5M | ($32M) | 3.9x | 3.4x | (0.6x) | (0.7x) | |||
This data is available for Pro users. Sign up to see all Profluent Bio competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Profluent Bio
| When was Profluent Bio founded? | Profluent Bio was founded in 2022. |
| Where is Profluent Bio headquartered? | Profluent Bio is headquartered in San Francisco, CA, United States. |
| Is Profluent Bio publicly listed? | No, Profluent Bio is a private, VC-backed company. |
| What is Profluent Bio's valuation? | Profluent Bio was last valued at $30M in its seed round in August 2022. |
| How much funding has Profluent Bio raised? | Profluent Bio has raised $150M across 3 funding rounds. |
| What was Profluent Bio's last funding round? | Profluent Bio's last funding round was a $106M undisclosed-stage round in November 2025, led by Altimeter Capital and Bezos Expeditions. |
| Who are Profluent Bio's investors? | Profluent Bio's investors include Air Street Capital, Insight Partners, AIX Ventures, Spark Capital, Phoenix Venture Partners, Altimeter Capital, Convergent Ventures, Bezos Expeditions and Jeff Dean. |
| Which companies are comparable to Profluent Bio? | Companies comparable to Profluent Bio include Aecor Bio, Talus Bio, Salt AI, AirezIQ, Gensight Biologics and BeyondSpring. |
See companies similar to Profluent Bio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.